CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis
CLIC3 is a TNBC-specific prognostic biomarker and therapeutic target. Its inhibition impedes TNBC aggressiveness, providing a foundation for targeted therapy development.
Authors
- Lina Yang (ORCID: https://orcid.org/0000-0002-1742-9941)
- Weimei Liu (ORCID: https://orcid.org/0000-0003-0982-6637)
- Shuangying Hao
- Shuai Yuan (ORCID: https://orcid.org/0009-0006-6153-194X)
- Lianyu Lin (ORCID: https://orcid.org/0009-0004-5061-9298)
- Jiangxia Li (ORCID: https://orcid.org/0000-0002-6249-286X)
- Meitian Ren
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Jiaozuo University (CN)
- Henan Polytechnic University (CN)
- Fujian Agriculture and Forestry University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s12885-025-15205-6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Henan Polytechnic University
- Science and Technology Department of Henan Province